Search Results - "Taylor, Renea A."

Preclinical Models of Prostate Cancer: Patient-Derived Xenografts, Organoids, and Other Explant Models by Risbridger, Gail P, Toivanen, Roxanne, Taylor, Renea A

“…Prostate cancer remains a lethal disease. Preclinical cancer models that accurately represent the tumors of the patients they are intended to help are…”
Get full text

Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer by Watt, Matthew J, Clark, Ashlee K, Selth, Luke A, Haynes, Vanessa R, Lister, Natalie, Rebello, Richard, Porter, Laura H, Niranjan, Birunthi, Whitby, Sarah T, Lo, Jennifer, Huang, Cheng, Schittenhelm, Ralf B, Anderson, Kimberley E, Furic, Luc, Wijayaratne, Poornima R, Matzaris, Maria, Montgomery, Magdalene K, Papargiris, Melissa, Norden, Sam, Febbraio, Maria, Risbridger, Gail P, Frydenberg, Mark, Nomura, Daniel K, Taylor, Renea A

“…Metabolism alterations are hallmarks of cancer, but the involvement of lipid metabolism in disease progression is unclear. We investigated the role of lipid…”
Get more information

Identification of Metabolically Distinct Adipocyte Progenitor Cells in Human Adipose Tissues by Raajendiran, Arthe, Ooi, Geraldine, Bayliss, Jackie, O’Brien, Paul E., Schittenhelm, Ralf B., Clark, Ashlee K., Taylor, Renea A., Rodeheffer, Matthew S., Burton, Paul R., Watt, Matthew J.

“…Adipocyte progenitor cells (APCs) provide the reservoir of regenerative cells to produce new adipocytes, although their identity in humans remains elusive…”
Get full text

Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories by Taylor, Renea A., Fraser, Michael, Livingstone, Julie, Espiritu, Shadrielle Melijah G., Thorne, Heather, Huang, Vincent, Lo, Winnie, Shiah, Yu-Jia, Yamaguchi, Takafumi N., Sliwinski, Ania, Horsburgh, Sheri, Meng, Alice, Heisler, Lawrence E., Yu, Nancy, Yousif, Fouad, Papargiris, Melissa, Lawrence, Mitchell G., Timms, Lee, Murphy, Declan G., Frydenberg, Mark, Hopkins, Julia F., Bolton, Damien, Clouston, David, McPherson, John D., van der Kwast, Theodorus, Boutros, Paul C., Risbridger, Gail P., Bristow, Robert G.

“…Germline mutations in the BRCA2 tumour suppressor are associated with both an increased lifetime risk of developing prostate cancer (PCa) and increased risk of…”
Get full text

Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories by Porter, Laura H, Lawrence, Mitchell G, Ilic, Dragan, Clouston, David, Bolton, Damien M, Frydenberg, Mark, Murphy, Declan G, Pezaro, Carmel, Risbridger, Gail P, Taylor, Renea A

“…Abstract Intraductal carcinoma of the prostate (IDC-P) is associated with poor prognosis. While it is often regarded as a rare pathology, the prevalence of…”
Get full text

Proteomic Profiling of Human Prostate Cancer-associated Fibroblasts (CAF) Reveals LOXL2-dependent Regulation of the Tumor Microenvironment[S] by Nguyen, Elizabeth V., Pereira, Brooke A., Lawrence, Mitchell G., Ma, Xiuquan, Rebello, Richard J., Chan, Howard, Niranjan, Birunthi, Wu, Yunjian, Ellem, Stuart, Guan, Xiaoqing, Wu, Jianmin, Skhinas, Joanna N., Cox, Thomas R., Risbridger, Gail P., Taylor, Renea A., Lister, Natalie L., Daly, Roger J.

“…Mass spectrometry-based (phospho)proteomics identified a prominent hub associated with collagens, receptor tyrosine kinase discoidin domain-containing receptor…”
Get full text

Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality? by Fidelito, Gio, Watt, Matthew J, Taylor, Renea A

“…Prostate cancer invokes major shifts in gene transcription and metabolic signaling to mediate alterations in nutrient acquisition and metabolic substrate…”
Get full text

The influence of BRCA2 mutation on localized prostate cancer by Taylor, Renea A., Fraser, Michael, Rebello, Richard J., Boutros, Paul C., Murphy, Declan G., Bristow, Robert G., Risbridger, Gail P.

“…A key challenge in the management of localized prostate cancer is the identification of men with a high likelihood of progression to an advanced, incurable…”
Get full text

Enduring epigenetic landmarks define the cancer microenvironment by Pidsley, Ruth, Lawrence, Mitchell G, Zotenko, Elena, Niranjan, Birunthi, Statham, Aaron, Song, Jenny, Chabanon, Roman M, Qu, Wenjia, Wang, Hong, Richards, Michelle, Nair, Shalima S, Armstrong, Nicola J, Nim, Hieu T, Papargiris, Melissa, Balanathan, Preetika, French, Hugh, Peters, Timothy, Norden, Sam, Ryan, Andrew, Pedersen, John, Kench, James, Daly, Roger J, Horvath, Lisa G, Stricker, Phillip, Frydenberg, Mark, Taylor, Renea A, Stirzaker, Clare, Risbridger, Gail P, Clark, Susan J

“…The growth and progression of solid tumors involves dynamic cross-talk between cancer epithelium and the surrounding microenvironment. To date, molecular…”
Get full text

Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor by Obinata, Daisuke, Takayama, Kenichi, Lawrence, Mitchell G, Funakoshi, Daigo, Hara, Makoto, Niranjan, Birunthi, Teng, Linda, Taylor, Renea A, Risbridger, Gail P, Takahashi, Satoru, Inoue, Satoshi

“…Prostate cancer is dependent on androgen receptor (AR) signaling, and androgen deprivation therapy (ADT) has proven effective in targeting prostate cancer…”
Get full text

FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer by Wang, Zifeng, Townley, Scott L., Zhang, Songqi, Liu, Mingyu, Li, Muqing, Labaf, Maryam, Patalano, Susan, Venkataramani, Kavita, Siegfried, Kellee R., Macoska, Jill A., Han, Dong, Gao, Shuai, Risbridger, Gail P., Taylor, Renea A., Lawrence, Mitchell G., He, Housheng Hansen, Selth, Luke A., Cai, Changmeng

“…FOXA family proteins act as pioneer factors by remodeling compact chromatin structures. FOXA1 is crucial for the chromatin binding of the androgen receptor…”
Get full text

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient‐derived xenograft (PDX) models by Navone, Nora M., van Weerden, Wytske M., Vessella, Robert L., Williams, Elizabeth D., Wang, Yuzhuo, Isaacs, John T., Nguyen, Holly M., Culig, Zoran, van der Pluijm, Gabri, Rentsch, Cyril A., Marques, Rute B., de Ridder, Corrina M. A., Bubendorf, Lukas, Thalmann, George N., Brennen, William Nathaniel, Santer, Frédéric R., Moser, Patrizia L., Shepherd, Peter, Efstathiou, Eleni, Xue, Hui, Lin, Dong, Buijs, Jeroen, Bosse, Tjalling, Collins, Anne, Maitland, Norman, Buzza, Mark, Kouspou, Michelle, Achtman, Ariel, Taylor, Renea A., Risbridger, Gail, Corey, Eva

“…Background While it has been challenging to establish prostate cancer patient‐derived xenografts (PDXs), with a take rate of 10‐40% and long latency time,…”
Get full text

OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer by Obinata, Daisuke, Funakoshi, Daigo, Takayama, Kenichi, Hara, Makoto, Niranjan, Birunthi, Teng, Linda, Lawrence, Mitchell G., Taylor, Renea A., Risbridger, Gail P., Suzuki, Yutaka, Takahashi, Satoru, Inoue, Satoshi

“…Androgen and androgen receptor (AR) targeted therapies are the main treatment for most prostate cancer (PC) patients. Although AR signaling inhibitors are…”
Get full text

Estrogen receptor-β activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFα mediated by McPherson, Stephen J, Hussain, Shirin, Balanathan, Preetika, Hedwards, Shelley L, Niranjan, Birunthi, Grant, Michael, Chandrasiri, Upeksha P, Toivanen, Roxanne, Wang, Yuzhuo, Taylor, Renea A, Risbridger, Gail P

“…Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are androgen-dependent diseases commonly treated by inhibiting androgen action. However, androgen…”
Get full text

Integrative characterisation of secreted factors involved in intercellular communication between prostate epithelial or cancer cells and fibroblasts by Wu, Yunjian, Clark, Kimberley C., Niranjan, Birunthi, Chüeh, Anderly C., Horvath, Lisa G., Taylor, Renea A., Daly, Roger J.

“…Reciprocal interactions between prostate cancer cells and carcinoma‐associated fibroblasts (CAFs) mediate cancer development and progression; however, our…”
Get full text

Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer by Fernandes, Rayzel C., Toubia, John, Townley, Scott, Hanson, Adrienne R., Dredge, B. Kate, Pillman, Katherine A., Bert, Andrew G., Winter, Jean M., Iggo, Richard, Das, Rajdeep, Obinata, Daisuke, Sandhu, Shahneen, Risbridger, Gail P., Taylor, Renea A., Lawrence, Mitchell G., Butler, Lisa M., Zoubeidi, Amina, Gregory, Philip A., Tilley, Wayne D., Hickey, Theresa E., Goodall, Gregory J., Selth, Luke A.

“…Potent therapeutic inhibition of the androgen receptor (AR) in prostate adenocarcinoma can lead to the emergence of neuroendocrine prostate cancer (NEPC), a…”
Get full text

A preclinical xenograft model of prostate cancer using human tumors by Lawrence, Mitchell G, Taylor, Renea A, Toivanen, Roxanne, Pedersen, John, Norden, Sam, Pook, David W, Frydenberg, Mark, Papargiris, Melissa M, Niranjan, Birunthi, Richards, Michelle G, Wang, Hong, Collins, Anne T, Maitland, Norman J, Risbridger, Gail P

“…Most cases of prostate cancer are now diagnosed as moderate-grade localized disease. These tumor specimens are important tools in the discovery and translation…”
Get full text

Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors by CENTENERA, Margaret M, GILLIS, Joanna L, YEADON, Trina, TILLEY, Wayne D, BUTLER, Lisa M, HANSON, Adrienne R, JINDAL, Shalini, TAYLOR, Renea A, RISBRIDGER, Gail P, SUTHERLAND, Peter D, SCHER, Howard I, RAJ, Ganesh V, KNUDSEN, Karen E

“…Targeting Hsp90 has significant potential as a treatment for prostate cancer, but prototypical agents such as 17-allylamino-17 demethoxygeldanamycin (17-AAG)…”
Get full text

Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target by Lee, Rachel S, Zhang, Luxi, Berger, Adeline, Lawrence, Mitchell G, Song, Jiangning, Niranjan, Birunthi, Davies, Rebecca G, Lister, Natalie L, Sandhu, Shahneen K, Rubin, Mark A, Risbridger, Gail P, Taylor, Renea A, Rickman, David S, Horvath, Lisa G, Daly, Roger J

“…Approximately 50% of prostate cancers harbor the TMPRSS2:ERG fusion, resulting in elevated expression of the ERG transcription factor. Despite the…”
Get full text

Human Epithelial Basal Cells Are Cells of Origin of Prostate Cancer, Independent of CD133 Status by Taylor, Renea A., Toivanen, Roxanne, Frydenberg, Mark, Pedersen, John, Harewood, Laurence, Australian Prostate Cancer Bioresource, Collins, Anne T., Maitland, Norman J., Risbridger, Gail P.

“…Normal prostatic epithelium is composed of basal and luminal cells. Prostate cancer can be initiated in both benign basal and luminal stem cells, but because…”
Get full text